|1.||Brown, G D: 1 article (07/2015)|
|2.||Hill, A D K: 1 article (07/2015)|
|3.||Huerre, Michel: 1 article (07/2015)|
|4.||Tibbitts, P: 1 article (07/2015)|
|5.||Ménard, Robert: 1 article (07/2015)|
|6.||Vaquero, Catherine: 1 article (07/2015)|
|7.||Lawson-Hogban, Nadou: 1 article (07/2015)|
|8.||Carroll, J S: 1 article (07/2015)|
|9.||Mécheri, Salah: 1 article (07/2015)|
|10.||Byrne, C: 1 article (07/2015)|
01/01/2015 - "Immunohistochemical labeling of HMGB2 in a panel of HNSCC tumors using tissue microarrays revealed overexpression in 77% (54 of 70) of tumors. "
01/01/2015 - "Overexpression of HMGB2 has been reported in various cancers, yet its role in HNSCC remains unclear. "
01/01/2013 - "HMGB2 was expressed in the nucleus in 35 of 39 (89.7%) renal clear cell cancers, while its expression in the cytosol was observed in only 7 case (17.9%). "
11/15/2010 - "Our clinical and in vitro data suggest that HMGB2 plays a significant role in tumor development and prognosis of HCC. "
01/01/2009 - "Focusing on four subclasses of follicular tumor, we explored the diagnostic potential of 12 selected markers (CASP10, CDH16, CLGN, CRABP1, HMGB2, ALPL2, ADAMTS2, CABIN1, ALDH1A3, USP13, NR2F2, KRTHB5) by real-time quantitative RT-PCR on 32 other new samples. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
03/01/2013 - "Our study revealed that HMGB2 is necessary to protect colorectal cancer cells from DNA damage and efficient DNA repair and p53-mediated downregulation is a critical mechanism of modulating HMGB2 expression."
03/01/2013 - "In addition, an exposure to radiation downregulated HMGB2 expression in colorectal cancer cells with an intact TP53 gene. "
03/01/2013 - "HMGB2 knockdown sensitized HCT-116 and HT-29 colorectal cancer cells to ionizing radiation. "
03/01/2013 - "High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell."
03/01/2013 - "Overexpression of high-mobility group box 2 (HMGB2) is recently reported in several malignant cancers and was correlated with poor response to preoperative chemoradiotherapy of colorectal cancer patients. "
|3.||Lung Neoplasms (Lung Cancer)
06/01/2014 - "Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response."
06/01/2014 - "The aim of the present study was to investigate the association of genetic polymorphisms in high mobility group box 1 and 2 (HMGB1 and HMGB2, respectively) with platinum-based chemotherapy responses in Chinese lung cancer patients. "
02/01/1998 - "Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC)."
01/01/1997 - "Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2."
06/01/1999 - "High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 have been identified as novel antigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCAs), and the existence of anti-HMG1 and anti-HMG2 antibodies in a population of patients with ulcerative colitis has been reported. "
|5.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
10/01/2013 - "HMGB2 expression was not changed in inflammatory bowel disease but was detected in certain stool samples of patients, whereas it was absent from control individuals. "
09/01/2012 - "Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype."
|1.||HMGB1 Protein (HMG1)
|2.||DNA (Deoxyribonucleic Acid)
|5.||Antineutrophil Cytoplasmic Antibodies (ANCA)
|6.||Proteins (Proteins, Gene)
|7.||Non-Histone Chromosomal Proteins
|8.||High Mobility Group Proteins
|1.||Drug Therapy (Chemotherapy)